The Global Exosome Market Report 2021: Market Size, Forecast, Trials and Trends -

DUBLIN--()--The "The Global Exosome Market - Market Size, Forecast, Trials, and Trends, 2021" report has been added to's offering.

Exosome-related technologies have been developing rapidly over the past few years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine and regenerative medicine. In particular, cancer derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection.

The cargo contained within exosomes can offer prognostic information for a range of diseases - including cardiovascular, renal, neurodegenerative, and metabolic diseases - as well as cancer. Researchers investigating exosome biomarkers have discovered, identified, and reported the presence of hundreds of biomolecules within the lumen of exosomes. This discovery has compelled a rapid rise in exosome-related cancer biomarker research, including the use of exosomes for the detection, monitoring, and treatment of a diverse range of oncologic conditions.

Importantly, exosomes are present within a diverse range of biofluids, including serum, plasma, urine, seminal fluid, CSF, saliva, tears and breast milk. For this reason, exosome-based diagnostics are minimally invasive, offering ease of use and speed of detection. Exosomes can also act as prognostic indicators and predictors of a patient's response to a specific course of treatment.

Exosomes are also being explored for their use as cell-free therapeutics. For example, if a patient has a disease caused by a missing or defective protein or microRNA, the patient's exosomes can be isolated, modified with the appropriate siRNA or protein and then injected back into the patient for treatment. There are also many approaches being researched for creating drug-loaded exosomes. Furthermore, exosomes can often exert powerful effects. For example, mesenchymal stem cell (MSC) derived exosomes have the capacity to suppress inflammation, prevent scar tissue formation, and mediate a healthy immune response.

This global market report explores the growing demand for exosome therapeutics, diagnostics, research tools, and manufacturing technologies. The report reveals trend rate data for exosome patents, grants, scientific publications, and clinical trials.

It highlights information about exosome industry partnerships, merger and acquisition (M&A) activity, and financing events. It features company profiles for 107 global competitors from across the exosome marketplace. Importantly, it presents market size determinations by market segment with forecasts through 2028.

The exosome industry is witnessing:

  • A surging number of scientific papers investigating exosomes and their applications
  • Rising numbers of clinicals trials investigating exosome therapeutics and diagnostics
  • Swelling appetite among investors for exosome technology
  • An increasingly competitive IP environment
  • A diverse range of co-development partnerships
  • Proliferating numbers of exosome competitors in all major life science markets worldwide

Profiles of Exosome Market Competitors

  • 101 Bio
  • Abbexa, Ltd.
  • Abnova
  • Adipomics, Inc.
  • Aegle Therapeutics
  • Aethlon Medical, Inc.
  • AgeX Therapeutics, Inc.
  • Alexerion Biotech Corp.
  • Anjarium Biosciences
  • antibodies-online GmbH
  • Aposcience AG
  • Aruna Bio
  • Avalon GloboCare Corp.
  • Aviva Systems Biology
  • Azymus Therapeutics
  • BARD1 Life Sciences, Ltd.
  • Beckman Coulter Life Sciences
  • Bio-Techne
  • BioCat GmbH
  • BioFluidica
  • Biorbyt, Ltd.
  • BioVision, Inc.
  • Capricor Therapeutics
  • CD Bioparticles
  • Cell Care Therapeutics
  • Cell Factory BVBA/Esperite NV
  • Cell Guidance Systems, Ltd.
  • Cellarcus Biosciences, Inc.
  • Ciloa
  • Clara Biotech
  • Codiak Biosciences
  • Creative Bioarray
  • Cusabio Technology LLC
  • Direct Biologics
  • DLdevelop
  • EVerZom
  • Evomic Science, LLC
  • Exerkine Corp.
  • ExoCan Healthcare Technologies, Pvt. Ltd.
  • ExoCoBio, Co., Ltd.
  • Exogenus Therapeutics
  • Exopharm
  • ExosomePlus
  • ExoVectory
  • GenWay Biotech, Inc.
  • Guardant Health, Inc.
  • HansaBioMed Life Sciences, Ltd.
  • Hitachi Chemical Diagnostics, Inc.
  • ILIAS Biologics, Inc.
  • Innocan Pharma Corporation
  • Innovex Therapeutics, S.L.
  • Invent Biotechnologies, Inc.
  • Invitrx Therapeutics
  • Izon Science, Ltd.
  • Kimera Labs, Inc.
  • LifeSpan BioSciences, Inc.
  • Lonza Group Ltd.
  • Mantra Bio
  • MDimune
  • miR Scientific
  • Mursla, Ltd.
  • MyBioSource, Inc.
  • NanoSomix, Inc.
  • Norgen Biotek Corp.
  • Novus Biologicals, LLC
  • nRichDx, Inc.
  • Oasis Diagnostics Corp.
  • OmniSpirant Limited
  • OriGene Technologies, Inc.
  • ReNeuron
  • RoosterBio, Inc.
  • Stemcell Medicine, Ltd.
  • System Biosciences, LLC
  • Tavec Pharma
  • Theoria Science, Inc.
  • Thermo Fisher Scientific
  • TransGen Biotech, Co., Ltd.
  • TriArm Therapeutics, Co., Ltd.
  • United Therapeutics Corp.
  • Vesigen Therapeutics, Inc.
  • VivaZome Therapeutics, Pvt. Ltd.
  • Xollent Biotech
  • XOStem, Inc.
  • YMIR Genomics LLC

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900